Gastroenterology and Hepatology

Episodes 1-15 of 66

• 

  CME/CE Meeting

  Treating At-Risk MASH: What Are You Waiting For?

  January 11, 2025

  Park City, Utah

  1.00 credits Learn more

• 

  RestartResume

  Effective Monitoring and Management of Adverse Effects in Metastatic ESCC

  MinuteCE®

  Effective Monitoring and Management of Adverse Effects in Metastatic ESCC

  • 

    

    Harry Yoon, MD

    Peer

  • 

    

    Jaffer Ajani, MD

    Peer

  0.75 program credits

• 

  MinuteCE®

  Differentiating First-Line Treatment Selection: Combination Immunotherapy and Chemotherapy Regimens for Metastatic ESCC

  • 

    

    Harry Yoon, MD

    Peer

  • 

    

    Jaffer Ajani, MD

    Peer

  0.75 credits 3 episodes

• 

  RestartResume

  The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC

  MinuteCE®

  The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC

  • 

    

    Harry Yoon, MD

    Peer

  0.75 program credits

• 

  RestartResume

  Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies

  MinuteCE®

  Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies

  • 

    

    Jaffer Ajani, MD

    Peer

  0.75 program credits

• 

  RestartResume

  Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective

  CME/CE

  Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective

  • 

    

    Naim Alkhouri, MD, FAASLD, DABOM

    Peer

  0.25 credits

• 

  RestartResume

  The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair’s Perspective

  CME/CE

  The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair’s Perspective

  • 

    

    Naim Alkhouri, MD, FAASLD, DABOM

    Peer

  0.25 credits

• 

  RestartResume

  Advances in the Treatment and Management of MASH: More Options, More Decisions

  CME/CE Broadcast Replay

  Advances in the Treatment and Management of MASH: More Options, More Decisions

  • 

    

    Mary E. Rinella, MD, FAASLD

    Peer

  • 

    

    Naga Chalasani, MD, FAASLD

    Peer

  • 

    

    Mazen Noureddin, MD, MHSc

    Peer

  1.50 credits

• 

  RestartResume

  Does Your Patient Have PBC?

  MinuteCE®

  Does Your Patient Have PBC?

  • 

    

    Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG

    Peer

  1.00 program credits

• 

  MinuteCE®

  Impacting Disease Outcomes and Quality of Life in PBC: Individualizing Treatment Selection and the Role of Novel Therapies

  • 

    

    Gideon Hirschfield, MB, BChir, PhD

    Peer

  • 

    

    Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG

    Peer

  • 

    

    Elizabeth K. Goacher, PA-C

    Peer

  1.00 credits 8 episodes

• 

  RestartResume

  Advances in the Treatment of PBC: Part 2

  MinuteCE®

  Advances in the Treatment of PBC: Part 2

  • 

    

    Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG

    Peer

  1.00 program credits

• 

  RestartResume

  Advances in the Treatment of PBC: Part 1

  MinuteCE®

  Advances in the Treatment of PBC: Part 1

  • 

    

    Gideon Hirschfield, MB, BChir, PhD

    Peer

  1.00 program credits

• 

  RestartResume

  Initiating Second-Line Therapy: What, When, and Then What?

  MinuteCE®

  Initiating Second-Line Therapy: What, When, and Then What?

  • 

    

    Gideon Hirschfield, MB, BChir, PhD

    Peer

  1.00 program credits

• 

  RestartResume

  PBC Is Risky Business

  MinuteCE®

  PBC Is Risky Business

  • 

    

    Gideon Hirschfield, MB, BChir, PhD

    Peer

  1.00 program credits

• 

  RestartResume

  PBC Target Practice: Normalization Is the New Norm

  MinuteCE®

  PBC Target Practice: Normalization Is the New Norm

  • 

    

    Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG

    Peer

  1.00 program credits

• 1
• 2
• 3
• 4
• 5
• Next